Immune microenvironment and molecular mechanisms in endometrial cancer: implications for resistance and innovative

Yijia Chen1, Lai Jiang1, Lanyue Zhang1

  • 1Clinical Medical College, Southwest Medical University, Luzhou, 646000, China.

Discover Oncology
|April 16, 2025
PubMed

Insights

This review explores endometrial cancer

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Endometrial cancer drug resistance is driven by aberrant signaling pathways.
  • The tumor immune microenvironment critically influences therapeutic outcomes.
  • Hypoxic metabolic reprogramming impacts anticancer therapies.

Purpose of the Study:

  • To systematically review molecular mechanisms of endometrial cancer and drug resistance.
  • To analyze the role of the immune microenvironment in cancer drug resistance.
  • To summarize advances in immunotherapy and individualized therapy for endometrial cancer.

Main Methods:

  • Systematic review of molecular mechanisms.
  • Analysis of signaling pathways and immune microenvironment.
  • Summary of recent therapeutic strategies.

Main Results:

  • Aberrant signaling pathways promote tumor proliferation, anti-apoptosis, and drug resistance.
  • Immune cells, checkpoints, and hypoxia significantly affect drug resistance.
  • Immunotherapy and individualized therapy show promise in advanced endometrial cancer.

Conclusions:

  • Targeting key pathways and modulating the immune microenvironment can overcome drug resistance.
  • Emerging therapeutic strategies aim to improve patient prognosis in endometrial cancer.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K